Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA approves Novo Nordisk's Norditropin for children with Turner syndrome

Sep. 26, 2007

NIDDK plans study of diabetes vaccine Diamyd for type 1 diabetes

Sep. 26, 2007

Studies of dapagliflozin, sergliflozin presented at EASD

Sep. 26, 2007

Recent FibroGen patent discloses novel HIF prolyl hydroxylase inhibitors

Sep. 25, 2007

Snapshots of dipeptidyl peptidase IV inhibitors from the EASD annual meeting

Sep. 25, 2007

Patient enrollment completed in phase II trial of Gabapentin GR for menopausal hot flashes

Sep. 21, 2007

Preclinical activity and pharmacokinetics of the novel PDE5 inhibitor lodenafil carbonate

Sep. 21, 2007

Intra-Cellular Therapies outlines portfolio of proprietary compounds for FSD

Sep. 21, 2007

E.U. grants Novo Nordisk approval for use of NovoRapid in elderly people

Sep. 20, 2007

FDA grants Preos orphan drug status in hypoparathyroidism indication

Sep. 20, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...